These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 11581239)

  • 41. Comparative in-vitro activity of quinupristin/dalfopristin against Enterococcus spp.
    Williams JD; Maskell JP; Whiley AC; Sefton AM
    J Antimicrob Chemother; 1997 May; 39 Suppl A():41-6. PubMed ID: 9511061
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of daptomycin susceptibility testing by Etest and the effect of different batches of media.
    Fuchs PC; Barry AL; Brown SD
    J Antimicrob Chemother; 2001 Oct; 48(4):557-61. PubMed ID: 11581238
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dalbavancin is active in vitro against biofilms formed by dalbavancin-susceptible enterococci.
    Neudorfer K; Schmidt-Malan SM; Patel R
    Diagn Microbiol Infect Dis; 2018 Jan; 90(1):58-63. PubMed ID: 29195766
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vitro activity of dalbavancin and five comparator agents against common and uncommon Gram-positive organisms isolated from cancer patients.
    Rolston KV; Wang W; Nesher L; Shelburne SA; Prince RA
    J Antibiot (Tokyo); 2016 May; 69(5):381-7. PubMed ID: 26626876
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [In vitro activity of daptomycin against VRE and MRSA strains].
    Aktaş G; Derbentli S
    Mikrobiyol Bul; 2014 Jan; 48(1):123-8. PubMed ID: 24506722
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The in vitro activity of daptomycin against Staphylococcus aureus and Enterococcus species.
    Richter SS; Kealey DE; Murray CT; Heilmann KP; Coffman SL; Doern GV
    J Antimicrob Chemother; 2003 Jul; 52(1):123-7. PubMed ID: 12805265
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antimicrobial activity and spectrum of daptomycin: results from the surveillance program in Australia and New Zealand (2008).
    Bell JM; Turnidge JD; Sader HS; Jones RN
    Pathology; 2010; 42(5):470-3. PubMed ID: 20632825
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro activity of daptomycin versus linezolid and vancomycin against gram-positive uropathogens and ampicillin against enterococci, causing complicated urinary tract infections.
    Wagenlehner FM; Lehn N; Witte W; Naber KG
    Chemotherapy; 2005 May; 51(2-3):64-9. PubMed ID: 15870498
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010-13).
    Mendes RE; Farrell DJ; Sader HS; Flamm RK; Jones RN
    J Antimicrob Chemother; 2015 Feb; 70(2):498-504. PubMed ID: 25362568
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model.
    Hall Snyder A; Werth BJ; Barber KE; Sakoulas G; Rybak MJ
    J Antimicrob Chemother; 2014 Aug; 69(8):2148-54. PubMed ID: 24777900
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pre-clinical experience with daptomycin.
    Hawkey PM
    J Antimicrob Chemother; 2008 Nov; 62 Suppl 3():iii7-14. PubMed ID: 18829726
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antimicrobial susceptibility of daptomycin and comparator agents tested against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: trend analysis of a 6-year period in US medical centers (2005-2010).
    Sader HS; Moet GJ; Farrell DJ; Jones RN
    Diagn Microbiol Infect Dis; 2011 Jul; 70(3):412-6. PubMed ID: 21546202
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Calcium-supplemented daptomycin Etest strips for susceptibility testing on Iso-Sensitest agar.
    Johnson AP; Mushtaq S; Warner M; Livermore DM
    J Antimicrob Chemother; 2004 May; 53(5):860-2. PubMed ID: 15056637
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vitro activity and post-antibiotic effect of quinupristin/dalfopristin (Synercid).
    Ling TK; Fung KS; Cheng AF
    Chemotherapy; 2001; 47(4):243-9. PubMed ID: 11399860
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method.
    Mendes RE; Farrell DJ; Sader HS; Streit JM; Jones RN
    Diagn Microbiol Infect Dis; 2015 Apr; 81(4):275-9. PubMed ID: 25618421
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus.
    Leuthner KD; Cheung CM; Rybak MJ
    J Antimicrob Chemother; 2006 Aug; 58(2):338-43. PubMed ID: 16787952
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative in-vitro activity of LY146032 a new peptolide, with vancomycin and eight other agents against gram-positive organisms.
    Benson CA; Beaudette F; Trenholm G
    J Antimicrob Chemother; 1987 Aug; 20(2):191-6. PubMed ID: 2822645
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In-vitro and in-vivo antibacterial activity of quinupristin/dalfopristin.
    Bouanchaud DH
    J Antimicrob Chemother; 1997 May; 39 Suppl A():15-21. PubMed ID: 9511057
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Telavancin Activity against gram-positive bacteria isolated from patients with skin and skin-structure infections.
    Pfaller MA; Rhomberg PR; Sader HS; Mendes RE; Jones RN
    J Chemother; 2010 Oct; 22(5):304-11. PubMed ID: 21123152
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vitro prevention of the emergence of daptomycin resistance in Staphylococcus aureus and enterococci following combination with amoxicillin/clavulanic acid or ampicillin.
    Entenza JM; Giddey M; Vouillamoz J; Moreillon P
    Int J Antimicrob Agents; 2010 May; 35(5):451-6. PubMed ID: 20185277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.